Recent studies in NSCLC patients with ALK or EGFR mutations and brain metastases, demonstrated greater benefit from the use of specific targeted therapies.
In this episode, Associate Professor Paul Mitchell, Medical Oncologist from the Olivia Newton-John Cancer Centre, is joined by Dr Fiona Hegi-Johnson, Radiation Oncologist, Peter MacCallum Cancer Centre in Victoria, and Dr Dasantha Jayamanne, Radiation Oncologist, Genesis Care and Royal Northshore Hospital in NSW to discuss the management of brain metastases in NSCLC. They discuss the current data, the role of stereotactic radiation therapy (SRS, SABR, SBRT) and molecular drivers of ALK and EGFR in the management of these patients.
Complex care is also discussed, as are intricacies and clinical considerations behind choosing and implementing care in NSCLC patients with brain metastases.
